Evidence map›Paper›PMID 20679622›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Melanie B Thomas, Deborah Jaffe, Michael M Choti, Jacques Belghiti, Steven Curley, Yuman Fong, Gregory Gores, Robert Kerlan, Phillipe Merle, Bert O'Neil and 7 more

Erratum issued Registry-linked trialAbstract readConsensus Development Conference, NIH
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06210334 (The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy), which is not on this map. Cited by 192 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed, 11 pooled it
14.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06210334 phase2unknown statusnot on this mapstarted 2024, after this paper: background citation

The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Tislelizumab and Lenvatinib in the Treatment of Hepatocellular Carcinoma (HCC) With Type IV(Vp4) Portal Vein Tumor Thrombus (PVTT): A Prospective, Single-armed, Stage II Clinical Trial

TypeinterventionalSponsorLi Xiao WeiRan2024 to 2026Enrolled54ConditionsHepatocellular Carcinoma With PVTTArmsTislelizumab, Lenvatinib
3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 11 syntheses or guidelines pooled it, 394 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013
    Pooled it
  11. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2011
    Guideline
  12. Trial
  13. Trial
  14. Trial
  15. PD-L1Technology in cancer research & treatment
    Trial
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Melanie B ThomasHollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA. thomasmb@musc.edu
Deborah Jaffe
Michael M Choti
Jacques Belghiti
Steven Curley
Yuman Fong
Gregory Gores
Robert Kerlan
Phillipe Merle
Bert O'Neil
Ronnie Poon
Lawrence Schwartz
Joel Tepper
Francis Yao
Daniel Haller
Margaret Mooney
Alan Venook
Radiation Oncology Associates · USSociety of Surgical Oncology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocelluar carcinoma (HCC) is the most common primary malignancy of the liver in adults and the third most common cause of cancer death worldwide. The incidence of HCC in the United States is rising steadily because of the prevalence of hepatitis C viral infection and other causes of hepatic cirrhosis. The majority of patients have underlying hepatic dysfunction, which complicates patient management and the search for safe and effective therapies. The Clinical Trials Planning Meeting (CTPM) in HCC was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to identify the key knowledge gaps in HCC and define clinical research priorities. The CTPM structured its review according to current evidence-based treatment modalities in HCC and prioritized the recommendations on the basis of the patient populations representing the greatest unmet medical need.

Indexed as

Carcinoma, HepatocellularClinical Trials as TopicCombined Modality TherapyHealth Planning GuidelinesHumansLiver NeoplasmsTreatment Outcome

Identifiers

PMID20679622
PMCPMC2940397
OpenAlexW2103362199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.